Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BMS 986020

Next Previous
Drug Profile

BMS 986020

Alternative Names: AM-152; BMS-986020

Latest Information Update: 16 Mar 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amira Pharmaceuticals
  • Developer Bristol-Myers Squibb; Duke University
  • Class Antifibrotics; Azabicyclo compounds; Carboxylic acids; Small molecules; Tetrazoles
  • Mechanism of Action Lysophosphatidic acid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Idiopathic pulmonary fibrosis

Most Recent Events

  • 17 May 2019 Discontinued - Phase-II for Idiopathic pulmonary fibrosis in Mexico, Peru, Colombia, Australia, Chile, USA (PO) before May 2019
  • 17 May 2019 Pharmacodynamics data from preclinical and clinical studies in Idiopathic pulmonary fibrosis presented at the 115th International Conference of the American Thoracic Society (ATS-2019)
  • 19 Sep 2018 Bristol-Myers Squibb terminates a phase-II clinical trials in Idiopathic pulmonary fibrosis in USA, Chile, Colombia, Mexico, Peru and Australia due to drug related adverse events (PO) (NCT01766817)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top